Drug Type Small molecule drug |
Synonyms DB 105, ORM-12741 |
Target |
Mechanism α2C-AR antagonists(Alpha-2c adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date26 Mar 2018 |
Sponsor / Collaborator |
Start Date24 Feb 2016 |
Sponsor / Collaborator |
Start Date14 Aug 2015 |
Sponsor / Collaborator [+1] |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggression | Phase 2 | FI | 14 Aug 2015 | |
Agitation | Phase 2 | FI | 14 Aug 2015 | |
Alzheimer Disease | Phase 2 | FI | 14 Aug 2015 | |
Scleroderma, Systemic | Phase 2 | GB | 01 Mar 2011 | |
Vasospasm | Phase 2 | GB | 01 Mar 2011 | |
Raynaud Disease | Phase 2 | GB | 01 Mar 2011 | |
Schizophrenia | Phase 2 | - | - | |
Schizophrenia | Phase 2 | - | - | |
Schizophrenia | Phase 2 | - | - | |
Schizophrenia | Phase 2 | - | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 100 | (Low Dose of ORM-12741) | obxtwbyqmo(rwxrrtfeto) = dwmofmzyhk ufjdjciyvw (oqpouwdxey, vslfbqkrem - zeaoinngjg) View more | - | 28 Apr 2021 | ||
(High Dose of ORM-12741) | obxtwbyqmo(rwxrrtfeto) = vtydxfzaxh ufjdjciyvw (oqpouwdxey, zvwdpnkmdp - tivlwivuuy) View more | ||||||
NCT01324518 (Pubmed) Manual | Phase 2 | 100 | ledmuvhjqd(gfjagmsswk): P-Value = 0.030 View more | Positive | 08 Dec 2016 | ||
Placebo |